These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34552881)

  • 1. Residual Volume of Lymph Nodes During Chemoradiotherapy Based Nomogram to Predict Survival of Nasopharyngeal Carcinoma Patient Receiving Induction Chemotherapy.
    Li Y; Zang J; Liu J; Luo S; Wang J; Hou B; Zhao L; Shi M
    Front Oncol; 2021; 11():739103. PubMed ID: 34552881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma.
    Liu Y; Zhang J; Wang J; Wu R; Huang X; Wang K; Qu Y; Chen X; Li Y; Zhang Y; Yi J
    Radiol Oncol; 2022 Dec; 56(4):479-487. PubMed ID: 36503717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI-Based Metastatic Nodal Number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma Patients: Potential Indications for Individual Induction Chemotherapy.
    Zhao Q; Dong A; Cui C; Ou Q; Ruan G; Zhou J; Tian L; Liu L; Ma H; Li H
    J Magn Reson Imaging; 2023 Jun; 57(6):1790-1802. PubMed ID: 36169976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
    Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of Prognostic Nomograms Based on Gross Tumor Volume and Cervical Nodal Volume for Nasopharyngeal Carcinoma Patients With Concurrent Chemoradiotherapy.
    Zhang CD; Li M; Hong YJ; Cai ZM; Huang KC; Lin ZX; Yang ZN
    Front Oncol; 2021; 11():682271. PubMed ID: 34262866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.
    Pan Y; Chen Z; Hong W; Huang Z; Li Y; Cai S; Lai J; Lu J; Qiu S
    BMC Cancer; 2024 May; 24(1):578. PubMed ID: 38734620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load.
    Jiang YT; Chen KH; Yang J; Liang ZG; Qu S; Li L; Zhu XD
    Front Oncol; 2021; 11():683475. PubMed ID: 34222003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers.
    Liu Q; Ma L; Ma H; Yang L; Xu Z
    Front Oncol; 2022; 12():1032213. PubMed ID: 36387244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
    He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
    Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram to predict survival and guide individualized induction chemotherapy in T3-4N1M0 nasopharyngeal carcinoma.
    Jiang YT; Chen KH; Liang ZG; Yang J; Qu S; Li L; Zhu XD
    Curr Probl Cancer; 2022 Dec; 46(6):100897. PubMed ID: 36162165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
    Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
    Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Yang H; Zhang R; Zhang R; Zhang B; Xie Y; Qin G; Mo Y; Ruan X; Jiang W
    Strahlenther Onkol; 2022 Sep; 198(9):828-837. PubMed ID: 35384452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.
    Lin C; Sun XS; Liu SL; Li XY; Lu N; Li XL; Tang LQ; Guo L
    Cancer Res Treat; 2020 Jul; 52(3):855-866. PubMed ID: 32164051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
    Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.